LON:TILS - Tiziana Life Sciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
GBX 39.40 0.00 (0.00 %)
(As of 07/16/2018 12:35 PM ET)
Previous CloseGBX 39.40
Today's RangeGBX 39 - GBX 39
52-Week RangeGBX 91 - GBX 240
Volume353 shs
Average Volume4,999 shs
Market Capitalization£122.09 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Tiziana Life Sciences logoTiziana Life Sciences plc, a clinical stage biotechnology company, focuses on the discovery and development of therapeutics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Milciclib (TZLS-201) that is in phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy; and Foralumab (TZLS-401), a human anti-CD3 antibody, which completed phase IIa clinical trials for autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, primary biliary cholangitis, ulcerative colitis, multiple sclerosis, autoimmune type-1 diabetes, inflammatory bowel diseases, and lupus. It also develops TZLS-501, a human anti IL-6R monoclonal antibody that is in pre-clinical development. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences plc is a subsidiary of Planwise Group Limited.

Receive TILS News and Ratings via Email

Sign-up to receive the latest news and ratings for TILS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange LON
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolLON:TILS
CUSIPN/A
Phone+44-20-74952379

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-457.77%
Return on Assets-208.53%

Miscellaneous

EmployeesN/A
Outstanding Shares123,830,000
Market Cap£122.09

The Truth About Cryptocurrencies

Tiziana Life Sciences (LON:TILS) Frequently Asked Questions

What is Tiziana Life Sciences' stock symbol?

Tiziana Life Sciences trades on the London Stock Exchange (LON) under the ticker symbol "TILS."

How were Tiziana Life Sciences' earnings last quarter?

Tiziana Life Sciences PLC (LON:TILS) issued its quarterly earnings results on Thursday, June, 7th. The biotechnology company reported ($6.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($10.00) by $3.60. View Tiziana Life Sciences' Earnings History.

What price target have analysts set for TILS?

1 equities research analysts have issued 1 year target prices for Tiziana Life Sciences' shares. Their forecasts range from GBX 400 to GBX 400. On average, they expect Tiziana Life Sciences' stock price to reach GBX 400 in the next twelve months. This suggests a possible upside of 915.2% from the stock's current price. View Analyst Ratings for Tiziana Life Sciences.

What is the consensus analysts' recommendation for Tiziana Life Sciences?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tiziana Life Sciences in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."

Who are some of Tiziana Life Sciences' key competitors?

Who are Tiziana Life Sciences' key executives?

Tiziana Life Sciences' management team includes the folowing people:
  • Mr. Gabriele Marco Antonio Cerrone, Founder & Exec. Chairman (Age 46)
  • Dr. Kunwar Shailubhai, CEO, Chief Scientific Officer & Exec. Director (Age 60)
  • Dr. Philip Boyd BSC, Ph.D., ACMA, Consultant
  • Dr. Andrea Brancale Ph.D., Scientific Founder
  • Mr. Richard Clarkson Ph.D., Scientific Founder

Has Tiziana Life Sciences been receiving favorable news coverage?

News stories about TILS stock have trended somewhat negative this week, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tiziana Life Sciences earned a media sentiment score of -0.05 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 46.74 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Tiziana Life Sciences?

Shares of TILS and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Tiziana Life Sciences' stock price today?

One share of TILS stock can currently be purchased for approximately GBX 39.40.

How big of a company is Tiziana Life Sciences?

Tiziana Life Sciences has a market capitalization of £122.09 million.

How can I contact Tiziana Life Sciences?

Tiziana Life Sciences' mailing address is 3rd Fl, 11-12 St. James's Square, LONDON, SW1Y 4LB, United Kingdom. The biotechnology company can be reached via phone at +44-20-74952379.


MarketBeat Community Rating for Tiziana Life Sciences (LON TILS)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  75 (Vote Outperform)
Underperform Votes:  142 (Vote Underperform)
Total Votes:  217
MarketBeat's community ratings are surveys of what our community members think about Tiziana Life Sciences and other stocks. Vote "Outperform" if you believe TILS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TILS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Featured Article: What does EPS mean?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.